Publications by authors named "Shahrbanoo Nakhaie"
Article Synopsis
- Researchers are exploring new ways to predict vesicoureteral reflux (VUR) due to the drawbacks of traditional radiological exams.
- This study tested the effectiveness of measuring neutrophil gelatinase-associated lipocalin (NGAL) levels in serum and urine to identify VUR in children with febrile urinary tract infections (UTIs).
- Results showed that urinary NGAL, with a cut-off value of 15 ng/mL, effectively indicates VUR with 82.6% sensitivity and 58.8% specificity, while serum NGAL levels did not correlate with VUR.
Background: Urinary tract infections (UTIs) are extremely prevalent bacterial infections among children. They have numerous potential causes. Without proper diagnosis and treatment, UTIs can lead to serious complications in children, including impaired growth, high blood pressure, protein in urine, and eventual chronic kidney disease.
View Article and Find Full Text PDFCystinosis is a multisystemic disease caused by the accumulation of cystine crystals in the kidney and many other organs. This disease most often involves children. Recent developments in the treatment procedures have improved the chance of patients surviving as long as puberty.
View Article and Find Full Text PDFShiga toxin induced Escherichia Coli (STEC) is associated with chronic kidney disease or neurologic disability. The aim of this study is to determine the prevalence of STEC identified in human studies in Iran. Search engines of PubMed, EMBASE, OVID, SCOPUS, Web of Science, Google Scholar, IranMedex, MagIran, SID and ganj.
View Article and Find Full Text PDFIntroduction: There is evidence of the effectiveness of rituximab in treatment of nephrotic syndrome in children. The present study aimed to assess safety and the therapeutic effectiveness of rituximab in steroid- and cyclosporine-resistant pediatric nephrotic syndrome.
Materials And Methods: Forty-three children with steroid- and cyclosporine-resistant or steroid- and cyclosporine-dependent noncongenital nephrotic syndrome were included in the study to receive intravenous rituximab, 375 mg/m2/wk, for 4 weeks.